Crystalline forms of nucleoside compounds
A novel crystalline form of ATV014 addresses solubility and stability issues, enhancing its therapeutic efficacy and storage stability, making it suitable for pharmaceutical applications.
JP7762931B2Active Publication Date: 2025-10-31SHENZHEN ANTIV PHARMA CO LTD
6 Cites 0 Cited by
Patent Information
- Application Number
- JP2024536512
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-12-23
- Filing Date
- 2022-05-17
- Publication Date
- 2025-10-31
- Estimated Expiration
- 2042-05-17
AI Technical Summary
Technical Problem
Existing forms of the nucleoside compound ATV014 lack optimal physicochemical properties such as solubility, stability, and bioavailability, which affect its therapeutic efficacy and storage stability.
Method used
Development of a novel crystalline form (Form I) of ATV014 with improved solubility, thermal stability, and low hygroscopicity, characterized by specific X-ray powder diffraction, differential scanning calorimetry, and thermogravimetric analysis patterns.
Benefits of technology
The novel crystalline form I exhibits enhanced stability under hygroscopic conditions, maintaining chemical purity and solubility, ensuring effective bioavailability and suitability for pharmaceutical formulations, particularly for treating viral infections like SARS-CoV-2.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides a crystalline form of a nucleoside compound, which is crystalline form I of ATV014, which has good solubility and thermal stability, and has a better bioavailability and dissolution curve in certain formulations. Its good permeability and thermal stability make it suitable for use in certain pharmaceutical formulations.
Need to check novelty before this filing date? Find Prior Art